• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical ophthalmology >Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions
【24h】

Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions

机译：Nampt / PBEF / visfatin血清水平：视网膜血管阻塞的新生物标志物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision.
机译：摘要：该研究的主要目的是定量分析具有视网膜血管阻塞（RVOs）病史的受试者的烟酰胺磷酸核糖基转移酶（Nampt / B细胞前集落增强因子1 / visfatin）的水平缺血和代谢能不足。进行了一项病例对照研究，研究对象是18名具有RVO病史的受试者以及6名健康志愿者。使用可商购的酶联免疫吸附测定试剂盒对血清Nampt水平进行定量。具有RVO病史的患者的血清Nampt水平比健康志愿者低79％（P <0.05）。 RVO的类型之间无统计学意义上的显着差异，特别是视网膜分支静脉阻塞（n = 7），视网膜中央静脉阻塞（n = 5），半视网膜静脉阻塞（n = 3）和视网膜中央动脉阻塞（n = 3; P = 0.69）。需要进一步的研究来确定Nampt表达的时间动力学，并确定Nampt是否可以代表一种新的生物标记物来识别高危人群，或者它是否是可治疗的靶点，并且有望缓解与该病相关的长期并发症即黄斑水肿，黄斑缺血，新血管形成和永久性视力丧失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号